PharmaCielo Ltd. PCLOF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 91.73% | 20.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 91.73% | 20.47% | |||
| Cost of Revenue | 96.48% | 212.41% | |||
| Gross Profit | 84.25% | -71.78% | |||
| SG&A Expenses | 65.92% | 115.78% | |||
| Depreciation & Amortization | 1,186.21% | 100.00% | |||
| Other Operating Expenses | -105.79% | 209.85% | |||
| Total Operating Expenses | -3.48% | 318.60% | |||
| Operating Income | 52.45% | -189.31% | |||
| Income Before Tax | -9.80% | -423.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.80% | -423.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.80% | -423.85% | |||
| EBIT | 52.45% | -189.31% | |||
| EBITDA | -4.86% | -126.86% | |||
| EPS Basic | 0.00% | -412.50% | |||
| Normalized Basic EPS | -45.45% | -320.00% | |||
| EPS Diluted | 0.00% | -412.50% | |||
| Normalized Diluted EPS | -45.45% | -320.00% | |||
| Average Basic Shares Outstanding | 8.96% | 1.06% | |||
| Average Diluted Shares Outstanding | 8.96% | 1.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||